Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Autor: Didier Riethmuller, Susanne K. Kjaer, Pierre Van Damme, Rosybel Drury, Kaatje Bollaerts, Elmar A. Joura, Karl Ulrich Petry, Chris J.L.M. Meijer, Paolo Bonanni, Margaret Stanley, Xavier Bosch, Benoît Soubeyrand
Rok vydání: 2018
Předmět:
Oncology
cervical cancer
Types 6
11
16
18
31
33
45
52
58
modelling
Cost-Benefit Analysis
Denmark
Uterine Cervical Neoplasms
human papillomavirus recombinant vaccine nonavalent
0302 clinical medicine
Cervix cancer
Risk Factors
Immunology and Allergy
030212 general & internal medicine
Finland
Cervical cancer
Vaccines
Synthetic
Norway
Incidence
Vaccination
Age Factors
Middle Aged
female genital diseases and pregnancy complications
Condylomata Acuminata
030220 oncology & carcinogenesis
Female
Monte Carlo Method
Engineering sciences. Technology
Research Paper
Adult
medicine.medical_specialty
Human papillomavirus
Adolescent
Càncer de coll uterí
Papillomaviruses
Immunology
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
Papillomavirus Vaccines
Papil·lomavirus
Biology
Aged
Pharmacology
Estimation
Active immunisation
business.industry
Papillomavirus Infections
Cancer
vaccination
medicine.disease
Residual risk
Human medicine
business
Zdroj: Dipòsit Digital de la UB
Universidad de Barcelona
Human vaccines & immunotherapeutics
Human Vaccines & Immunotherapeutics
Petry, K U, Bollaerts, K, Bonanni, P, Stanley, M, Drury, R, Joura, E, Kjaer, S K, Meijer, C J L M, Riethmuller, D, Soubeyrand, B, Van Damme, P & Bosch, X 2018, ' Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine ', Human Vaccines and Immunotherapeutics, vol. 14, no. 7, pp. 1800-1806 . https://doi.org/10.1080/21645515.2018.1450125
ISSN: 2164-5515
DOI: 10.1080/21645515.2018.1450125
Popis: Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low risk types 6 and 11, causing genital warts. Objective: To estimate the lifetime risk (up to the age of 75 years) for developing cervical cancer after vaccinating a HPV naive girl (e.g. 9 to 12 years old) with the 9vHPV vaccine in the hypothetical absence of cervical cancer screening. Methods: We built Monte Carlo simulation models using historical pre-screening age-specific cancer incidence data and current mortality data from Denmark, Finland, Norway, Sweden and the UK. Estimates of genotype contribution fractions and vaccine efficacy were used to estimate the residual lifetime risk after vaccination assuming lifelong protection. Results: We estimated that, in the hypothetical absence of cervical screening and assuming lifelong protection, 9vHPV vaccination reduced the lifetime cervical cancer and mortality risks 7-fold with a residual lifetime cancer risks ranging from 1/572 (UK) to 1/238 (Denmark) and mortality risks ranging from 1/1488 (UK) to 1/851 (Denmark). After decades of repetitive cervical screenings, the lifetime cervical cancer and mortality risks was reduced between 2- and 4-fold depending on the country. Conclusion: Our simulations demonstrate how evidence can be generated to support decision-making by individual healthcare seekers regarding cervical cancer prevention.
Databáze: OpenAIRE
Externí odkaz: